The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Forty 18-year-old social drinkers will be selected from the sample tested in specific aim 1 ("Prospective Assessment of Adolescent Drinking Trajectories With Computer-Assisted Self-administration of Ethanol (CASE)"; ClinicalTrials.gov identifier: NCT01063166). The functional magnetic resonance imaging blood-oxygen-level-dependent (fMRI BOLD) activity related to disinhibition measured with the Stop Signal task will be assessed during a continuous infusion of alcohol, clamping the arterial Breath Alcohol Concentration (aBAC) at 60 mg% for approximately one hour. It will be examined whether this fMRI BOLD activity is associated with the initial drinking trajectories and the alcohol consumption at age 18 and at age 20 identified in specific aim 1. Furthermore, fMRI will be used with the Taylor Aggression Paradigm to determine which brain areas mediate increased physical aggression during the same continuous infusion of alcohol as described above. All participants will undergo an alcohol and a placebo fMRI session.
Collaboration on Alcohol Self Administration in Adolescents and Young Adults - Specific Aim 2: To Examine the Effect of Acute Alcohol Administration on Forebrain Disinhibition Using Functional Magnetic Resonance Imaging (fMRI)
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
Drug: Placebo - half-normal saline
Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 19 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Residents living within 15 km (9.5 miles) from downtown Dresden
male and female Caucasian volunteers aged 18 years/0 months to 19 years/11 months;
written informed consent by the subject;
habitual social drinking during the two months preceding participation, defined by at least one drinking day in any two weeks-interval;
at least one prior experience of alcohol intoxication
being able to abstain from tobacco use for four hours without developing nicotine withdrawal symptoms;
effective contraception in female participants;
consenting to abstain from any illegal substance use for 2 weeks prior to participation;
living within 15 km (9.5 miles) from downtown Dresden;
sufficient information concerning alcohol use in both parents and in at least four second-degree relatives
prior medical treatment due to alcohol use;
current or prior history of any serious disease, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, alcohol or drug dependence, but not alcohol abuse;
current history of Axis-I psychiatric illness, including premenstrual dysphoric disorder;
current or prior history of alcohol-induced flushing reactions;
positive urine screen for cannabinoids, cocaine, amphetamines, opiates, or benzodiazepines;
light or non-drinkers: averaging less than 2 standard drinks per week in the preceding two months;
intention to become pregnant
pregnancy or positive urine pregnancy screening or breast-feeding;
any alcohol intake on the test day or the day before;
use of medications known to interact with alcohol within 2 weeks of the study;
positive hepatitis or HIV at screening, provided the subject consented to these tests
any conditions posing safety issues with the fMRI scan, such as ferromagnetic implants, cardiac pacemakers or insulin pumps